ABOUT
OXLUMO® (lumasiran)
Grace*Person with PH1

*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

Image

BACKED BY THE LARGEST
PLACEBO-CONTROLLED STUDY
IN PH1 AND THE ONLY OPTION

ACROSS ALL AGES
AND STAGES

OF KIDNEY FUNCTION*†1-5

PH1=primary hyperoxaluria type 1.

In clinical trials, OXLUMO was evaluated in both pediatric (including infants) and adult patients, including those with an estimated glomerular filtration rate (eGFR) ranging from 8.6 mL/min/1.73 m2 to ≥90 mL/min/1.73 m2 and patients on hemodialysis.1,6

OXLUMO's effects on urinary and plasma oxalate levels were measured in clinical trials.

MECHANISM OF ACTION

OXLUMO is a liver-targeted RNA interference (RNAi) therapeutic1

OXLUMO acts upstream of the metabolic defect in AGT to reduce oxalate production1

OXLUMO is a double-stranded, small interfering RNA (siRNA) designed for specific uptake into hepatocytes1

OXLUMO harnesses RNAi, a natural process that reduces the production of a protein1

Image

OXLUMO acts at the main site of oxalate overproduction1

In PH1

Impaired function of AGT results in overproduction of oxalate7-9

Image

With OXLUMO

Targeting the glycolate oxidase (GO) enzyme upstream of AGT results in a reduction in the amount of oxalate produced1

Image

AGT=alanine:glyoxylate aminotransferase; RNA=ribonucleic acid.

Providing relief with OXLUMO

Image
Dr. Stone
Dr. Stone
“Before OXLUMO was available, our conversations with patients and families revolved around supportive care. Now that OXLUMO is available, we talk to patients about this medication that can actually treat the disease and not just manage its symptoms."
Learn more about Dr. Stone’s experience.
Download

Mechanism of Action of OXLUMO

This video provides a brief overview of PH1 and how OXLUMO works.

Image

Want to see how OXLUMO is dosed?

Use the dosing guide to learn which dosing regimen is right for your patient.

Show Me the Dosing Regimens 

Download the Dosing Guide

Image

WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?

Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.

Let's Connect

Image
'

There’s more to learn about OXLUMO

When you sign up, we will keep you informed with updates and resources.

Sign Me Up

Image
Alnylam Assist™ Logo

Alnylam Assist® provides support services for patients throughout their treatment with OXLUMO

Alnylam Assist® includes patient services in 4 key areas, including understanding insurance benefits and financial assistance options for eligible patients,* helping ensure access to therapy, and providing PH1 disease education.

Let's Get Started

Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

NEXT:

SEE EFFICACY AND SAFETY DATA FROM CLINICAL TRIALS WITH OXLUMO1

 EFFICACY & SAFETY

1. OXLUMO Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc. 2. RIVFLOZA Prescribing Information. Plainsboro, NJ: Dicerna Pharmaceuticals, Inc. 3. Garrelfs SF, Frishberg Y, Hulton SA, et al. N Engl J Med. 2021;384(13):1216-1226. 4. Sas DJ, Magen D, Hayes W, et al. Genet Med. 2022;24(3):654-662. 5. Sellier-Leclerc A-L, Magen D, Shasha-Lavsky H, et al. Am J Kidney Dis. 2025;86(2):285-288. 6. Michael M, Groothoff JW, Shasha-Lavsky H, et al. Am J Kidney Dis. 2023;81(2):145-155.e1. 7. Milliner DS, Harris PC, Sas DJ, Cogal AG, Lieske JC. In: Adam MP, Feldman J, Mirzaa GM, et al, eds. GeneReviews. University of Washington, Seattle; 1993-2024. 8. Cochat P, Rumsby G. N Engl J Med. 2013;369(7):649-658. 9. Cochat P, Hulton SA, Acquaviva C, et al. Nephrol Dial Transplant. 2012;27(5):1729-1736.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common (≥20%) adverse reaction reported in patients treated with OXLUMO was injection site reaction. Injection site reactions included erythema, swelling, pain, hematoma, pruritus, and discoloration.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.